Scotiabank lowered the firm’s price target on Apellis (APLS) to $30 from $35 and keeps a Sector Perform rating on the shares. The company missed on both the topline and bottom line, the analyst tells investors. Additionally, Syfovre and Empaveli came short of expectations, with Syfovre’s launch facing headwinds due to anticipated unfavorable gross-to-net adjustments, the firm adds. While the firm sees a path for continued revenue growth as Syfovre gains preferred status from payers, this growth will likely be more muted than what has been seen previously.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis price target lowered to $40 from $65 at Oppenheimer
- Apellis price target lowered to $51 from $63 at Citi
- Apellis price target lowered to $30 from $43 at Wells Fargo
- Apellis price target lowered to $47 from $61 at BofA
- Apellis price target lowered to $57 from $83 at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
